
Ricky Turgeon PharmD
@ricky_turgeon
CV Pharmacist-Researcher, Assistant Prof @ubcpharmacy EBM & shared decision making enthusiast, all-around nerd.
Slowly moving to rickyturgeon.bsky.social
ID: 2398230380
http://nerdcat.org 19-03-2014 17:45:34
4,4K Tweet
1,1K Takipçi
338 Takip Edilen


Pharmacotherapy in heart failure: Simultaneous initiation of the 4 standard heart failure medications with biweekly adjustment provided the highest cost utility compared with other strategies. ➡️ cmaj.ca/lookup/doi/10.… Ricky Turgeon PharmD UBC Pharm Sci

Simultaneous initiation of the 4 standard HFrEF medications with biweekly adjustment provided the highest cost utility compared with other strategies Systems of care are needed to enable rapid initiation and sustained use of HFrEF meds Steve Greene Javed Butler Harriette Van Spall, MD MPH 🇨🇦



Going to #AHA24? Come talk to Blair MacDonald about our latest modeling study of pharmacotherapy for heart failure with reduced ejection fraction, this time looking at 1-year efficacy/safety of different quadruple therapy sequencing strategies: eppro01.ativ.me/appinfo.php?pa…




More data supporting the role of pharmacists in HF and associated conditions. ACCP Cardiology PRN

William Baker ACCP Cardiology PRN …another 🪵 on the 🔥 jamanetwork.com/journals/jaman…

❣️ Elevate Patient Care with CSHP and Canadian Cardiovascular Pharmacist Network! Gain the tools and insights to deliver exceptional care for patients with ASCVD at the Canadian Pharmacy Atherosclerotic Cardiovascular Disease Symposium. 🎟️: CSHP.ca/ASCVDS



Join me at the 2nd Canadian Cardiovascular Pharmacist Network CSHP/SCPRS CVD Symposium--focusing on ASCVD--on Feb 1 (to kick off Heart Month). The program is virtual (and will also be available to view after the event) and fully accredited. #pharmacy #CVD ccs.ca/event/canadian…




David J. Cohen, MD, MSc Davide Capodanno TCTMD PCRonline 🫀 Attributes of ideal NI trial: 90-95% power Margin fixed as relative difference, RR 1.5-1.2 Separate assessment of efficacy & safety Criterion for win: NI efficacy, superior safety NI met with ITT & PP analysis How many NI trials, especially monotherapy vs DAPT trials, meet these?

I was honored to co-lead this effort with Alex Chan and a wonderful groups of authors. Give it a read. UConn Pharmacy